Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01955941 · ClinicalTrials.gov registry record
Vascular Response to Brachytherapy Using Functional OCT
A clinical trial, sponsored by OHSU Knight Cancer Institute.
- Completed
- Registry status
- 49
- Enrollment target
NCT01955941: Completed study, sponsored by OHSU Knight Cancer Institute.
NCT01955941 is a clinical trial that has completed, run by OHSU Knight Cancer Institute. The registered enrollment target is 49 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01955941 has completed, sponsored by OHSU Knight Cancer Institute.
- COMPLETED
- Registry status
- 49 participants
- Enrollment target
Study Summary
The purpose of this study is to learn how blood flows to tumors in patients treated with I-125 plaque brachytherapy for uveal melanoma.
Primary Outcome
The purpose of this study is to learn how blood flows to tumors in important structures of the eye in patients treated with I-125 plaque brachytherapy for uveal melanoma. This will be assessed using Doppler OCT and OCT angiography technologies.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2013-10 |
| Est. Completion | 2021-11-22 |
What the finished NCT01955941 record still lists
NCT01955941 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 49 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01955941 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01955941 about?
NCT01955941 is a clinical study titled "Vascular Response to Brachytherapy Using Functional OCT". The purpose of this study is to learn how blood flows to tumors in patients treated with I-125 plaque brachytherapy for uveal melanoma.
What is the current status of trial NCT01955941?
This trial is currently completed. The enrollment target is 49 participants. The study started on 2013-10. Estimated completion is 2021-11-22.
Who is sponsoring clinical trial NCT01955941?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia